Core Viewpoint - WuXi Biologics (02269) experienced a 2.1% decline in stock price, trading at 32.58 HKD per share with a transaction volume of 304 million HKD as of 09:46 on August 26 [1] Group 1: Company Overview - WuXi Biologics is a leading global provider of biologics services, offering comprehensive, integrated, and highly customized services throughout the entire process from discovery and development to production of biologics [1] - The company held a 48% market share in China's biologics R&D market in 2016 and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Group 2: Financial Performance - As of the mid-year report in 2025, WuXi Biologics reported total revenue of 9.953 billion CNY and a net profit of 2.339 billion CNY [2]
药明生物(02269)下跌2.1%，报32.58元/股